NCT05574998 2022-10-12
FTANLCNDG
Qianfoshan Hospital
Phase 2 Unknown
Clinical Trials
14 trialsNCT05529355 2022-09-07
Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer
Anhui Chest Hospital
Phase 2 Unknown
NCT04303130 2020-03-10
Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT03614065 2018-08-03
Endostar Combine With Radiotherapy in Brain Metastasis of NSCLC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT03123445 2017-04-21
Endostar First-line Treatment of Advanced NSCLC
China Medical University, China
Phase 2 Unknown
NCT02579564 2016-10-21
Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients
Xinqiao Hospital of Chongqing
Phase 3 Unknown
NCT02497118 2015-07-14
Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage â…¢A NSCLC
Tianjin Medical University Cancer Institute and Hospital
Phase 4 Completed
NCT02005120 2013-12-20
Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC
Zhejiang University
Phase 2 Unknown
NCT02001168 2013-12-04
Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in Phaseâ… B
Xinjiang Medical University
Phase 3 Unknown
NCT01218594 2012-10-17
DP-EN-RT
Sun Yat-sen University
Phase 2 Unknown
NCT01687439 2012-09-19
Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)
Fudan University
Phase 2 Completed
NCT01158144 2010-07-08
Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902)
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT01124253 2010-05-17
Dengshan
Shanghai Jiao Tong University School of Medicine
Phase 3 Completed
NCT01028729 2009-12-09
NSCLC
Simcere Pharmaceutical Co., Ltd
Phase 4 Unknown